Log in

NASDAQ:AKBA - Akebia Therapeutics Stock Price, Forecast & News

-0.25 (-2.78 %)
(As of 02/16/2020 02:25 PM ET)
Today's Range
Now: $8.75
50-Day Range
MA: $7.55
52-Week Range
Now: $8.75
Volume1.03 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. Read More…

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:AKBA



Sales & Book Value

Annual SalesN/A



Next Earnings Date3/24/2020 (Estimated)

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc (NASDAQ:AKBA) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.09. The biopharmaceutical company earned $91.98 million during the quarter, compared to analyst estimates of $93.94 million. View Akebia Therapeutics' Earnings History.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Akebia Therapeutics.

What price target have analysts set for AKBA?

5 analysts have issued 12 month price targets for Akebia Therapeutics' shares. Their forecasts range from $9.00 to $17.00. On average, they anticipate Akebia Therapeutics' stock price to reach $13.80 in the next year. This suggests a possible upside of 57.7% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.

What is the consensus analysts' recommendation for Akebia Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.

What are Wall Street analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:
  • 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/21/2019)
  • 2. HC Wainwright analysts commented, "We continue to believe that positive outcomes, on both safety and efficacy, from all four studies is highly likely, and with data directly comparing its outcomes to the current standard of care in both DD and NDD patients, we continue to believe Akebia is well positioned for clinical, regulatory and commercial success. Affirm Buy. $17 PT. We employ a rNPV model, driven by U.S. sales of vadadustat (early 2022 launch, 75% POS, $2.5B peak U.S. sales) and Auryxia (peak sales of $409M in 2024) out to 2028 (zero terminal value) discounted at 12.5%. Risks to our investment thesis and target price include: (1) failure in pivotal Phase 3 vadadustat studies; (2) failure to secure regulatory approval of vadadustat; (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing; and (4) intellectual property opposition." (9/9/2019)

Has Akebia Therapeutics been receiving favorable news coverage?

Headlines about AKBA stock have trended neutral this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akebia Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Akebia Therapeutics.

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 9,340,000 shares, a drop of 5.1% from the January 15th total of 9,840,000 shares. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is currently 6.3 days. Currently, 8.8% of the company's stock are sold short. View Akebia Therapeutics' Current Options Chain.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Chesapeake Energy (CHK), Gilead Sciences (GILD), FireEye (FEYE), Energy Transfer LP Unit (ET), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), AT&T (T), Keryx Biopharmaceuticals (KERX) and AbbVie (ABBV).

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the folowing people:
  • Mr. John P. Butler MBA, CEO, Pres & Director (Age 55)
  • Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)
  • Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)
  • Ms. Nicole R. Hadas, SVP, Chief Legal Officer & Sec. (Age 46)
  • Mr. Douglas Jermasek, VP of Marketing & Strategy

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Baupost Group LLC MA (16.45%), State Street Corp (2.89%), Point72 Asset Management L.P. (1.98%), Rice Hall James & Associates LLC (1.18%), Goldman Sachs Group Inc. (0.63%) and Charles Schwab Investment Management Inc. (0.61%). Company insiders that own Akebia Therapeutics stock include John P Butler, Steven C Gilman and Steven Keith Burke. View Institutional Ownership Trends for Akebia Therapeutics.

Which institutional investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, State Street Corp, UBS Group AG, Old West Investment Management LLC, Rice Hall James & Associates LLC, Rafferty Asset Management LLC, Boston Partners and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Akebia Therapeutics.

Which institutional investors are buying Akebia Therapeutics stock?

AKBA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., AQR Capital Management LLC, Russell Investments Group Ltd., Renaissance Technologies LLC, California Public Employees Retirement System and FMR LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman and Steven Keith Burke. View Insider Buying and Selling for Akebia Therapeutics.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $8.75.

MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  348 (Vote Outperform)
Underperform Votes:  294 (Vote Underperform)
Total Votes:  642
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel